Navigation Links
Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Date:4/7/2009

sults could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure of our products to obtain such approval; uncertainties or differences in interpretation of clinical trial results; our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Glycotex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... Calif. , March 26, 2015 Huntington ... Gabriel Valley to perform transcatheter aortic valve replacement (TAVR), ... procedure is a revolutionary new way to replace an ... of a heart lung machine. The procedure ... team led by Azhil ( Alex) Durairaj , MD, ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
(Date:3/28/2015)... Tucson, AZ (PRWEB) March 28, 2015 Coffee ... could also help protect you from gum disease, researchers have ... protected against gum disease. , Coffee contains antioxidants. Antioxidants fight ... is the question researchers at Boston Univ. Henry M. Goldman ... published in the August 2014 issue of the Journal of ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... standard chemo boosted survival, study found , FRIDAY, ... myeloma live longer when thalidomide is added to standard ... finding could be the first real treatment advance for ... , Standard chemotherapy for elderly patients involves two drugs, ...
... Presentation to highlight milestones including phase III development of ... What: Horizon Therapeutics, Inc. is pleased to announce that ... M.D., Ph.D., chief executive officer, will ... including its recent completion of Series C financing, and ...
... Lilly and Company,announced today that as a part ... Administration (FDA), the company has updated the Zyprexa(R),(olanzapine) ... This new labeling information is available at ... reflect recently completed pooled analyses of Lilly,s,clinical trial ...
... SAN FRANCISCO, Calif., Oct. 5 Anesiva,Inc. (Nasdaq: ... company,s,chief executive officer, will present at the Biotechnology Industry,Organization,s ... am PDT in San Francisco. To access the ... http://www.anesiva.com and go to the Investors page, ...
... NGOs, Sports, Academic, and Business Leaders Issue a, Call to ... ... Disabilities, ... organizations (NGOs), sports,academic and business representing 60 countries gathered today ...
... Everything Is A Victory, Especially When People, Control Own Lives; But ... Weiner Seeks Prosecution Of Everyone In Her Entourage Including Coach; ... Other Athletes And Children Beware, ... 2000 Olympic medals, or the Olympics should force her to,return them," ...
Cached Medicine News:Health News:Thalidomide Improves Outcomes for Older Myeloma Patients 2Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 2Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 3Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 4Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 5Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 6Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 7Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 8Health News:Global Leaders Converge for Special Olympics Global Policy Summit 2Health News:Global Leaders Converge for Special Olympics Global Policy Summit 3Health News:Global Leaders Converge for Special Olympics Global Policy Summit 4Health News:Marian Jones Should Return Olympic Medals, Says Ex-White House Drug Spokesman Bob Weiner 2
These backbiters enable simple access to the anterior horn of the meniscus....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: